Ignite Creation Date:
2025-12-24 @ 11:51 AM
Ignite Modification Date:
2025-12-30 @ 2:49 AM
Study NCT ID:
NCT07181161
Status:
RECRUITING
Last Update Posted:
2025-12-17
First Post:
2025-09-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Sponsor:
AstraZeneca
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Prostate Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Metastatic Castration-Resistant Prostate Cancer | View |
| None | Dose escalation study | View |
| None | Anti-cancer agents | View |
| None | Antibody-drug conjugate | View |
| None | Anti-Six-transmembrane epithelial antigen of the prostate 2 (anti-STEAP2) | View |
| None | Metastatic castration resistant prostate cancer (mCRPC) | View |
| None | AZD0516 | View |